Drugs / Dalpiciclib
Trials 109 · started per year
today
2
4
6
11
9
22
17
10
17
11
2016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 121 trials | ||||||
| Phase 1 | NCT07652762 | Jun 2026 → Aug 2028 expected | CDK4 linked melanoma, meningioma | Capital Medical University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06225921 | Dec 2023 → Jan 2025 | esophageal squamous cell carcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT06109207 | Oct 2023 → Oct 2024 overdue | head and neck squamous cell carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06099990 | Oct 2023 → Dec 2028 expected | prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05628870 | Feb 2023 → Jun 2025 overdue | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05515289 | Dec 2022 → Aug 2023 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05586841 | Oct 2022 → Dec 2025 | hormone receptor-positive breast cancer | Beijing 302 Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04989829 | Dec 2021 → Jan 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04993430 | Oct 2021 → Dec 2026 expected | breast carcinoma by gene expression profile | Shanghai Hengrui Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05103826 | Oct 2021 → Jun 2023 | estrogen-receptor positive breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04973020 | Sep → Oct 2021 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04667156 | Dec 2020 → Jan 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04631575 | Dec 2020 → Mar 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04616742 | Nov 2020 → Jan 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04439578 | Jun → Aug 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04423601 | Jun → Jul 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04301804 | Mar → May 2020 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05354336 | Jun → Aug 2019 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 1 | NCT03480256 | Jul 2018 → Nov 2019 | gastric cancer | Peking University | Unknown | No outcome recorded |
| Phase 1 | NCT02684266 | Mar 2016 → Jun 2019 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02671513 | Jan → Nov 2016 | melanoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT07189884 | Sep 2025 → Jun 2026 overdue | breast cancer | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06208410 | Jan 2024 → Feb 2027 expected | neoplasm | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06167694 | Dec 2023 → Jun 2026 overdue | breast carcinoma | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05792410 | Apr 2023 → Feb 2024 | Her2-receptor negative breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05574881 | Sep 2022 → Jan 2025 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05176080 | Dec 2021 → Jul 2024 | breast cancer | Henan Cancer Hospital | Terminated | Mixed |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03772353 | May 2019 → Jun 2023 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03601598 | Jul 2018 → Jul 2019 | hepatocellular carcinoma, non-small cell lung carcinoma | Harbin Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03481998 | Mar 2018 → Jul 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 262 trials · 1 met primary | ||||||
| Phase 2 | NCT07815522 | Oct 2026 → Oct 2028 expected | salivary gland carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07826052 | Sep 2026 → Sep 2031 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07610720 | Jun 2026 → Nov 2028 expected | HER2 positive breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07539753 | Jun 2026 → Aug 2029 expected | Her2-receptor negative breast cancer, metastatic malignant neoplasm in the brain | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07618923 | Jun 2026 → Jun 2028 expected | hormone receptor-positive breast cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527806 | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07581834 | Jan 2026 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07307287 | Dec 2025 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07238881 | Nov 2025 → Dec 2026 expected | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06556862 | Oct 2025 → Dec 2026 expected | hormone receptor-positive breast cancer | Beijing 302 Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07492394 | Sep 2025 → Dec 2026 expected | breast cancer | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07101159 | Sep 2025 → Dec 2031 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07037199 | Aug 2025 → Jun 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06970912 | Aug 2025 → Dec 2029 expected | female breast carcinoma, hormone receptor-positive breast cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07810088 | Jun 2025 → Jun 2028 expected | hormone receptor-positive breast cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT07285382 | Jun 2025 → Dec 2027 expected | hormone receptor-positive breast cancer | wanghaibo | Recruiting | No outcome recorded |
| Phase 2 | NCT06650748 | May 2025 → Oct 2027 expected | breast cancer | Peking University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06935188 | Apr 2025 → Dec 2028 expected | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07130643 | Dec 2024 → Dec 2026 expected | hormone receptor-positive breast cancer | Xinhong Wu, PhD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06684600 | Nov 2024 → Oct 2025 overdue | esophageal squamous cell carcinoma | Peking University | Recruiting | No outcome recorded |
| Phase 2 | NCT06599216 | Oct 2024 → Mar 2026 overdue | hormone receptor-positive breast cancer | Harbin Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06552858 | Sep 2024 → Sep 2026 overdue | ovarian cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06495515 | Aug 2024 → Jul 2025 overdue | female breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06363734 | Apr 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06199271 | Jan 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | Zhongzheng Xiang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05979220 | Dec 2023 → Jun 2024 overdue | breast cancer | Shuangyue Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06341894 | Nov 2023 → Jun 2027 expected | female breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06243185 | Nov 2023 → Dec 2024 | ovarian carcinoma | Fengzhi Feng | Unknown | No outcome recorded |
| Phase 2 | NCT06107673 | Sep 2023 → Dec 2026 expected | breast cancer | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06133088 | Aug 2023 → Dec 2024 | Her2-receptor negative breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05952128 | Jul 2023 → Dec 2024 | sarcoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05806671 | May 2023 → Jan 2025 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT07014410 | Feb 2023 → Dec 2027 expected | breast cancer | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05638594 | Dec 2022 → Dec 2025 overdue | breast cancer | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05721443 | Dec 2022 → Nov 2024 | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Completed | No outcome recorded |
| Phase 2 | NCT05577923 | Nov 2022 → Sep 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05577442 | Oct 2022 → Oct 2023 | breast neoplasm | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05640778 | Oct 2022 → Oct 2024 | luminal B breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT05512780 | Sep 2022 → Aug 2023 | cancer | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04997798 | Sep 2022 → Dec 2024 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT05724355 | Sep 2022 → Oct 2023 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05469750 | Aug 2022 → Aug 2023 | breast cancer | Fujian Medical University Union Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05800756 | Aug 2022 → May 2024 | breast cancer | Yantai Yuhuangding Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05512416 | Aug 2022 → Aug 2023 | breast cancer | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Phase 2 | NCT05480280 | Jul 2022 → Dec 2023 | colorectal cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05205200 | Jun 2022 → Feb 2025 overdue | breast cancer, metastatic malignant neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05431504 | Jun 2022 → Dec 2025 overdue | female breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05328440 | May 2022 → Jun 2024 | breast cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05228951 | Feb → Dec 2022 overdue | breast cancer | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05185869 | Jan 2022 → Jul 2025 | pancreatic ductal adenocarcinoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04836520 | Aug 2021 → Feb 2023 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04733417 | May 2021 → Aug 2022 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04866381 | Apr 2021 → Apr 2023 | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04486911 | Jul 2020 → Dec 2026 expected | breast cancer | Shengjing Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04293276 | Apr 2020 → Aug 2021 | breast cancer | Henan Cancer Hospital | Unknown | Met primary |
| Phase 2 | NCT04236310 | Jan 2020 → Dec 2022 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04095390 | Sep 2019 → Nov 2021 | HER2 positive breast carcinoma | Jinming Yu | Unknown | No outcome recorded |
| Phase 2 | NCT03993964 | Aug 2019 → Oct 2020 | breast cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07653451 | Jul 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06009627 | Apr 2023 → Mar 2025 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 37 trials · 2 met primary | ||||||
| Phase 3 | NCT07432178 | Apr 2026 → Mar 2031 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07005557 | Jun 2025 → May 2030 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07615751 | Feb 2025 → Dec 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05861830 | May 2023 → Dec 2025 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04842617 | Apr 2021 → Oct 2026 expected | hormone receptor-positive breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03966898 | Jul 2019 → Dec 2022 | female breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 3 | NCT03927456 | Jun 2019 → Dec 2021 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06613373 | Oct 2024 → Oct 2025 overdue | breast cancer | Jiangsu Famous Medical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07706933 | Aug 2026 → Jun 2028 expected | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06810492 | Apr → Dec 2025 overdue | female breast carcinoma | Hongmei Zheng, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06711094 | Jan 2025 → Dec 2027 expected | hormone receptor-positive breast cancer | Fujian Medical University | Not yet recruiting | No outcome recorded |
| — | NCT06605690 | Oct 2024 → Aug 2025 overdue | breast cancer | Liu Shu | Not yet recruiting | No outcome recorded |
| — | NCT05132790 | Sep 2023 → Dec 2024 overdue | breast cancer | Shengjing Hospital | Active not recruiting | No outcome recorded |
| Comparator or background therapy13 trials | ||||||
| Phase 1 | NCT05189717 Background | Feb 2022 → Oct 2024 | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT07180160 Background | Sep 2025 → Sep 2027 expected | female breast carcinoma | Wenjin Yin | Recruiting | No outcome recorded |
| Phase 2 | NCT06149130 Background | Jan 2024 → Nov 2025 overdue | breast cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06176534 Comparator | Jan 2024 → Dec 2025 overdue | Her2-receptor negative breast cancer, female breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05949541 Background | Jul 2023 → Jul 2026 overdue | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05759572 Background | Mar 2023 → Jul 2026 overdue | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05759546 Background | Feb 2023 → Nov 2025 overdue | breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05463601 Background | Aug 2022 → Jan 2025 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07354022 Background | May 2026 → Dec 2028 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07467330 Background | Nov 2025 → Dec 2031 expected | breast cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07207070 Background | Nov 2025 → May 2029 expected | breast cancer | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06612814 Background | Sep 2024 → Oct 2027 expected | breast carcinoma | Zhimin Shao | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06447623 Background | Jun 2024 → Feb 2027 expected | hormone receptor-positive breast cancer | Fudan University | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 124 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dalpiciclib | “Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative...” PMID 37182538 ↗ May 202386“Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone...” NCT06447623 ↗ “Dalpiciclib (SHR6390) is a novel inhibitor of cyclin-dependent kinase 4/6 which demonstrated promising anti-tumor potency in preclinical models.” PMID 33845905 ↗ Apr 2021 “Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.” PMID 34737452 ↗ Nov 2021 “sequential Trastuzumab rezetecan followed by CDK4/6 inhibitors (Dalpiciclib, Abemaciclib, Ribociclib, Palbociclib) plus endocrine therapy” NCT07037199 ↗ “HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.” NCT05628870 ↗ “The participants receive cetuximab in combination with Dalpiciclib until termination criteria are met.” NCT06935188 ↗ “Dalpiciclib: 125 mg, administered orally once daily at approximately the same time each day.” NCT07615751 ↗ “All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)” NCT07005557 ↗ “dalpiciclib:125mg once a day for 3 weeks and stop for 1 week. Q4W.” NCT07810088 ↗ “CDK4/6 inhibitors：dalpiciclib,palbociclib,abemaciclib,ribociclib” NCT07130643 ↗ |
| Known as | Dalpiciclib Isethionate | “The recommended dose of dalpiciclib isethionate is 150 mg once daily for 21 consecutive days, followed by a 7-day treatment break (3-on/1-off schedule), constituting a 28-day...” NCT07815522 ↗1“Dalpiciclib Isethionate tablets, 125mg, oral administration on days 1 to 21, followed by a 7-day drug holiday, every 4 weeks” NCT06684600 ↗ |
| Known as | Dalpiciclib Isethionate Tablets | “Dalpiciclib Isethionate Tablets: 125 mg orally every 28 days as a treatment cycle, with continuous medication for the first 3 weeks (Day 1 to Day 21), and rest (no medication)...” NCT07189884 ↗ |
| Known as | SHR-6390 | “Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone...” NCT06447623 ↗39“Drug Dalpiciclib 100mg/125mg/150mg PO qd, administered only from day1 to day 21 every cycle until disease progression, unacceptable toxicity or death. 28 days as a treatment...” NCT05952128 ↗ “Pyrotinib Maleate, Trastuzumab, SHR6390(Dalpiciclib) and Letrozole in Combination for Neoadjuvant Treatment of Stage II-III TPBC” NCT05228951 ↗ “SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off)” NCT04215003 ↗ “combined with CDK4/6 inhibitor SHR6390 150mg qd” NCT03805399 ↗ |
| Action | Inhibit | “SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor.” NCT02671513 ↗ |
| Modality | Small molecule | “SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor.” NCT02671513 ↗ |
| Route | Oral | “given orally” NCT02671513 ↗ |
| Target | CDK4 | “SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor.” NCT02684266 ↗ |